160 related articles for article (PubMed ID: 21619535)
1. Antibody targeting of TGF-β in cancer patients.
Lonning S; Mannick J; McPherson JM
Curr Pharm Biotechnol; 2011 Dec; 12(12):2176-89. PubMed ID: 21619535
[TBL] [Abstract][Full Text] [Related]
2. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.
Lenferink AE; Cantin C; Nantel A; Wang E; Durocher Y; Banville M; Paul-Roc B; Marcil A; Wilson MR; O'Connor-McCourt MD
Oncogene; 2010 Feb; 29(6):831-44. PubMed ID: 19935703
[TBL] [Abstract][Full Text] [Related]
4. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.
Wojtowicz-Praga S
Invest New Drugs; 2003 Feb; 21(1):21-32. PubMed ID: 12795527
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.
Jennings MT; Hart CE; Commers PA; Whitlock JA; Martincic D; Maciunas RJ; Moots PL; Shehab TM
J Neurooncol; 1997 Feb; 31(3):233-54. PubMed ID: 9049853
[TBL] [Abstract][Full Text] [Related]
6. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.
Du S; Bouquet S; Lo CH; Pellicciotta I; Bolourchi S; Parry R; Barcellos-Hoff MH
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):91-9. PubMed ID: 25835621
[TBL] [Abstract][Full Text] [Related]
8. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-β: A therapeutic target for cancer.
Haque S; Morris JC
Hum Vaccin Immunother; 2017 Aug; 13(8):1741-1750. PubMed ID: 28575585
[TBL] [Abstract][Full Text] [Related]
11. Targeting aberrant TGF-beta signaling in pre-clinical models of cancer.
Mourskaia AA; Northey JJ; Siegel PM
Anticancer Agents Med Chem; 2007 Sep; 7(5):504-14. PubMed ID: 17896911
[TBL] [Abstract][Full Text] [Related]
12. TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.
Yang P; Zhang Y; Markowitz GJ; Guo X; Wang XF
Methods Mol Biol; 2016; 1344():325-39. PubMed ID: 26520135
[TBL] [Abstract][Full Text] [Related]
13. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
[TBL] [Abstract][Full Text] [Related]
14. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.
Pardali K; Moustakas A
Biochim Biophys Acta; 2007 Jan; 1775(1):21-62. PubMed ID: 16904831
[TBL] [Abstract][Full Text] [Related]
15. Targeting the transforming growth factor-beta signalling pathway in metastatic cancer.
Korpal M; Kang Y
Eur J Cancer; 2010 May; 46(7):1232-40. PubMed ID: 20307969
[TBL] [Abstract][Full Text] [Related]
16. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Inan S; Vatansever S; Celik-Ozenci C; Sanci M; Dicle N; Demir R
Histol Histopathol; 2006 Oct; 21(10):1055-64. PubMed ID: 16835828
[TBL] [Abstract][Full Text] [Related]
17. Targeting TGF-β Signaling in Cancer.
Colak S; Ten Dijke P
Trends Cancer; 2017 Jan; 3(1):56-71. PubMed ID: 28718426
[TBL] [Abstract][Full Text] [Related]
18. Anti-transforming growth factor-beta monoclonal antibodies prevent lung injury in hemorrhaged mice.
Shenkar R; Coulson WF; Abraham E
Am J Respir Cell Mol Biol; 1994 Sep; 11(3):351-7. PubMed ID: 8086171
[TBL] [Abstract][Full Text] [Related]
19. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
